Current reports
6-K
Current report (foreign)
22 Apr 24
6-K
Current report (foreign)
16 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Current report (foreign)
29 Mar 24
6-K
FDA ODAC votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI based on results from the Phase 3 CARITUDE-4 study
15 Mar 24
6-K
Current report (foreign)
13 Mar 24
6-K
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
11 Mar 24
6-K
Current report (foreign)
23 Feb 24
6-K
Legend Biotech Corporation 6-K
23 Jan 24
6-K
Legend Biotech Corporation 6-K
23 Jan 24
Registration and prospectus
F-3ASR
Automatic shelf registration (foreign)
19 Mar 24
F-3ASR
Automatic shelf registration (foreign)
26 May 23
424B5
Prospectus supplement for primary offering
8 May 23
D
$200.00 mm in equity, sold $200.00 mm, 1 investor
28 Apr 23
424B5
Prospectus supplement for primary offering
27 Jul 22
424B5
Prospectus supplement for primary offering
25 Jul 22
424B5
Prospectus supplement for primary offering
17 Dec 21
FWP
Free writing prospectus
16 Dec 21
424B5
Prospectus supplement for primary offering
14 Dec 21
424B3
Prospectus supplement
14 Jul 21
Proxies
No filings
Other
UPLOAD
Letter from SEC
15 Sep 23
CORRESP
Correspondence with SEC
8 Sep 23
UPLOAD
Letter from SEC
31 Aug 23
UPLOAD
Letter from SEC
27 Feb 23
CORRESP
Correspondence with SEC
11 Oct 22
UPLOAD
Letter from SEC
6 Oct 22
CORRESP
Correspondence with SEC
30 Sep 22
UPLOAD
Letter from SEC
2 Sep 22
EFFECT
Notice of effectiveness
14 Jul 21
CORRESP
Correspondence with SEC
9 Jul 21
Ownership
SC 13G/A
BlackRock Inc.
5 Apr 24
144
Notice of proposed sale of securities
28 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
144
Notice of proposed sale of securities
26 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
144
Notice of proposed sale of securities
19 Mar 24
144/A
Notice of proposed sale of securities (amended)
28 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
144
Notice of proposed sale of securities
27 Feb 24